Results 21 to 30 of about 5,633 (190)
Therapeutic Advances in Musculoskeletal Disease, 2022 Background: To evaluate the safety, tolerability, and efficacy of SHR4640, a highly selective urate transporter-1 inhibitor, in combination with febuxostat, in patients with primary hyperuricemia.
Honghu Tang +15 more
doaj +1 more source
, 2021 The US FDA-mandated CARES trial, published in 2018, reported increased all-cause and cardiovascular (CV) death in participants randomized to febuxostat compared with allopurinol.
Lisa K. Stamp +9 more
core +1 more source
PLoS ONE, 2022 Background Although hyperuricemia is associated with chronic kidney disease, whether and how it should be managed for renoprotection remains debatable.
Seokwoo Park +4 more
doaj +3 more sources
Arthritis Research & Therapy, 2018 Background The purpose of this study was to assess the comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults.
Jasvinder A. Singh, John D. Cleveland
doaj +1 more source
Cobalt‐Catalyzed Radical Ligand Transfer (RLT) Enables Remote‐Markovnikov Hydroamination of Alkenes
Angewandte Chemie, EarlyView.A cobalt‐catalyzed remote‐Markovnikov 1,3‐hydroamination of allyl carboxylates proceeds through MHAT, 1,2‐radical acyloxy migration (1,2‐RAM), and radical ligand transfer (RLT) from a Co‐N intermediate, providing protected amino alcohols. ABSTRACT Amino alcohols are prevalent in pharmaceuticals, agrochemicals, and functional materials, yet ...
Arman Khosravi +7 more
wiley +2 more sources
Angewandte Chemie, EarlyView.Photochemically generated phosphoryl radicals from iminyl phosphines enable strain‐release addition to azabicyclobutanes, providing access to elusive N‐phosphoryl azetidines. Combined experimental, computational, and EPR studies reveal an unconventional water‐assisted photoredox pathway.
Chandu G. Krishnan +4 more
wiley +2 more sources
Scientific Reports, 2023 Hyperuricemia relates to chronic kidney disease (CKD) progression and impaired endothelial function. Febuxostat is potent and effective for decreasing serum uric acid levels.
Naowanit Nata +4 more
doaj +1 more source
, 2022 Background: To re-evaluate comparative cardiovascular (CV) safety of febuxostat versus allopurinol among pa-tients with gout following recent accumulated use of febuxostat.Methods: Using 2011-2019 Korea National Health Insurance database, we conducted a ...
You-Jung Ha +13 more
core +1 more source
Efficacy and Safety of Different Doses of Urico-Lowering Agents in The Treatment of Gout with Hyperuricemia: A Systematic Review and Network Meta-Analysis [PDF]
BIO Web of ConferencesObjectives: To systematically evaluate the efficacy and safety of different doses of uric acid- lowering drugs (allopurinol, febuxostat, and benzbromarone) in patients with gout with hyperuricemia by using the method of reticulated Meta-analysis. Methods:
Wen Jie +6 more
doaj +1 more source
Journal of International Medical Research, 2020 Objective To measure the effect of febuxostat on the serum levels of uric acid (sUA) and the proinflammatory cytokines interleukin (IL)-6, IL-17 and tumour necrosis factor-α (TNF-α) in Chinese Han patients with gout and hyperuricaemia.
Yuan-Yuan Huang +4 more
doaj +1 more source